Anacor Pharmaceuticals Announces Positive Results From the First of Two Phase III Trials of Tavaborole for Onychomycosis

Anacor Pharmaceuticals announced positive preliminary results from the first of two Phase III trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the U.S.
MarketWatch